120
Participants
Start Date
February 4, 2021
Primary Completion Date
January 31, 2023
Study Completion Date
January 31, 2023
TQB3616 capsules
TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
Fulvestrant injection
Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
RECRUITING
The Fifth Medical Center of PLA General Hospital, Beijing
NOT_YET_RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
NOT_YET_RECRUITING
The Second Hospital of Dalian Medical University, Dalian
NOT_YET_RECRUITING
Harbin Medical University Affiliated Cancer Hospital, Harbin
NOT_YET_RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Jiangsu Province Hospital, Nanjing
NOT_YET_RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Guangdong General Hospital, Guangzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
NOT_YET_RECRUITING
The Second Affiliated Hospital of PLA Air Force Military Medical University, Xi’an
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
NOT_YET_RECRUITING
Gansu Provincial Hostipal, Lanzhou
NOT_YET_RECRUITING
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi
NOT_YET_RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY